Suppr超能文献

5-(噻吩-2-基)异恶唑作为靶向雌激素受体α的新型抗乳腺癌药物:合成、生物学评价、研究及分子动力学模拟

5-(Thiophen-2-yl)isoxazoles as novel anti-breast cancer agents targeting ERα: synthesis, biological evaluation, studies, and molecular dynamics simulation.

作者信息

Pattanayak Paramita, Nikhitha Sripathi, Halder Debojyoti, Ghosh Balaram, Chatterjee Tanmay

机构信息

Department of Chemistry, Birla Institute of Technology and Science, Pilani (BITS Pilani), Hyderabad Campus Jawahar Nagar Hyderabad 500078 Telangana India

Epigenetic Research Laboratory, Department of Pharmacy, Birla Institute of Technology and Science, Pilani (BITS Pilani) Hyderabad Campus, Jawahar Nagar Hyderabad 500078 Telangana India

出版信息

RSC Med Chem. 2025 Jun 25. doi: 10.1039/d5md00339c.

Abstract

Herein, we report the design and synthesis of novel 5-(thiophen-2-yl)-4-(trifluoromethyl)isoxazoles (), and evaluation of their anti-cancer activities. Based on the molecular structure of our previously developed isoxazole-based anti-breast cancer lead molecule, 3-(3,4-dimethoxyphenyl)-5-(thiophen-2-yl)-4-(trifluoromethyl)isoxazole (TTI-4), we designed a set of 14 new analogues of TTI-4. The are a synthetically challenging class of molecules, and we synthesized them with high purity by utilizing our in-house developed novel synthetic strategy, , metal-free, cascade regio- and stereoselective trifluoromethyloximation, cyclization, and elimination strategy, with readily available α,β-unsaturated ketones by using commercially available and cheap reagents such as CFSONa and BuONO (cost-effective and sustainable synthesis). Subsequently, the anti-cancer activities of the newly synthesized molecules were evaluated against various cancer cell lines such as MCF-7, 4T1, and PC-3, and the molecules showed potential and more selective cytotoxicity against the human breast cancer cell line, MCF-7, among others. The screening revealed a new molecule, , 5-(thiophen-2-yl)-4-(trifluoromethyl)-3-(3,4,5-trimethoxyphenyl)isoxazole (TTI-6), possessing an IC value of 1.91 μM against MCF-7, is superior to the previous lead molecule (TTI-4) and also the best anti-cancer agent among all. The structure-activity relationship (SAR) studies revealed the importance of an unsubstituted thiophene ring in the 5th position, a -CF functional group in the 4th position, and a highly electron-rich benzene ring bearing three -OCH functional groups in the 3rd position of the isoxazole core to have superior activity. Further studies with TTI-6, such as apoptosis induction, cell cycle analysis, and nuclear staining, revealed an apoptotic cell death mechanism. The molecular docking, induced fit analysis, and ADMET studies further supported the effects of various functional groups of on their anti-breast cancer activity by inhibiting the estrogen receptor alpha (ERα), a crucial nuclear hormone receptor involved in gene regulation that plays an important role in several human cancers.

摘要

在此,我们报告了新型5-(噻吩-2-基)-4-(三氟甲基)异恶唑的设计与合成,并对其抗癌活性进行了评估。基于我们先前开发的基于异恶唑的抗乳腺癌先导分子3-(3,4-二甲氧基苯基)-5-(噻吩-2-基)-4-(三氟甲基)异恶唑(TTI-4)的分子结构,我们设计了一组14种TTI-4的新类似物。它们是一类合成具有挑战性的分子,我们利用我们内部开发的新型合成策略,即无金属、级联区域和立体选择性三氟甲基肟化、环化和消除策略,通过使用市售且廉价的试剂如CFSONa和BuONO(经济高效且可持续的合成),以高纯度合成了它们。随后,对新合成的分子针对多种癌细胞系如MCF-7、4T1和PC-3进行了抗癌活性评估,这些分子对人乳腺癌细胞系MCF-7等表现出潜在且更具选择性的细胞毒性。初步筛选发现了一种新分子,5-(噻吩-2-基)-4-(三氟甲基)-3-(3,4,5-三甲氧基苯基)异恶唑(TTI-6),其对MCF-7的IC值为1.91 μM,优于先前的先导分子(TTI-4),也是所有分子中最佳的抗癌剂。构效关系(SAR)研究表明,异恶唑核心第5位未取代的噻吩环、第4位的-CF官能团以及第3位带有三个-OCH官能团的高度富电子苯环对于具有优异活性至关重要。对TTI-6的进一步研究,如凋亡诱导、细胞周期分析和核染色,揭示了一种凋亡细胞死亡机制。分子对接、诱导契合分析和ADMET研究进一步支持了TTI-6的各种官能团通过抑制雌激素受体α(ERα)对其抗乳腺癌活性的影响,ERα是一种关键的核激素受体,参与基因调控,在多种人类癌症中起重要作用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/96fe/12264769/874847cd655d/d5md00339c-f1.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验